What's Happening?
Tiziana Life Sciences has announced promising clinical data from its Expanded Access Program for intranasal foralumab, a fully human anti-CD3 monoclonal antibody, in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). The data,
updated as of March 2026, indicates that the treatment is well tolerated and shows trends towards stabilization of disability and improvements in fatigue. The study involved 14 patients and demonstrated a favorable safety profile with no new safety signals. The treatment showed a trend towards reduced Confirmed Disability Progression and 64% of patients experienced a clinically meaningful improvement in fatigue. Dr. Howard L. Weiner, a key figure in the study, highlighted the potential of intranasal foralumab as a novel therapy for SPMS, emphasizing its excellent tolerability and encouraging clinical trends.
Why It's Important?
The development of intranasal foralumab is significant as it offers a potential new treatment paradigm for progressive forms of multiple sclerosis, where current options are limited. The positive safety and clinical trend data suggest that this treatment could address unmet needs in managing SPMS, a condition that significantly impacts patients' quality of life. The unique mechanism of intranasal foralumab, which reduces neuroinflammation, positions it as a promising candidate in the field of neurodegenerative disease treatment. The success of this program could lead to broader applications of Tiziana's innovative drug delivery technologies, potentially transforming the landscape of immunotherapy.
What's Next?
Tiziana Life Sciences plans to advance the intranasal foralumab program towards regulatory approval, leveraging the positive data from the Expanded Access Program. The company is also conducting a Phase 2a trial to further evaluate the efficacy and safety of the treatment. As the program progresses, Tiziana aims to solidify its position in the market for neuroinflammatory and neurodegenerative disease therapies. The continued development and potential approval of intranasal foralumab could lead to increased interest and investment in alternative routes of immunotherapy.
